Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 134
Selected: 0
NCT IDTitle
NCT00216125Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
NCT03448718Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
NCT04849364Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT03528408Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
NCT01232881Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT00216164Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03400254Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
NCT03871153Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
NCT04895046Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
NCT02101385Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT03737123Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT03557918Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT01186458Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT04470674Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
NCT03396471Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
NCT03041181Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT05498272Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT01074970PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
NCT00216203Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
NCT00216099Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT00890955Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
NCT05502315Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT00732303Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
NCT01732107Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
NCT02343952Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT02500901Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT03451331Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT02581059Efficacy of Ginseng for Patients on Regorafenib
NCT00234494Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
NCT06503614A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT03035630Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT04848337Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT01215136First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT00216138Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
NCT03117309Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT04589832Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
NCT01177683Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
NCT00773474Lonafarnib in Metastatic Breast Cancer
NCT03317158Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT02982720Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
NCT00572572Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT00526799Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
NCT02549209Pembro/Carbo/Taxol in Endometrial Cancer